Compendium of Cancer Genome Aberrations

Volunteer Assignments and Opportunities: Difference between revisions

← Older editNewer edit →
VisualWikitext
Snehal.Patel (talk | contribs)
editor
270 edits
No edit summary
Snehal.Patel (talk | contribs)
editor
270 edits
No edit summary
(137 intermediate revisions by 9 users not shown)
Line 1: Line 1:
Welcome! 


*For assignments, please see the "Author" column below.  If no name is present, volunteer to create content!
*We will be creating content for all entities with genetic findings in the current WHO Classification of Tumours books.  '''<u>If there is an entity not yet listed below that you would like to author in any WHO book, we would be happy to create a page for you now</u>'''.
*To volunteer, please '''[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]''' with your page of interest.
*'''<u>NOTE: A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated by mid-2023; we're working on a plan to align the related CCGA content to the new structure.</u>'''
__TOC__
==WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content==
{| class="wikitable"
{| class="wikitable"
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content
|-
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Disease'''!!'''Page Type'''!!'''Author'''
Line 25: Line 17:
|
|
|Fabiola Quintero-Rivera (FQR)
|Fabiola Quintero-Rivera (FQR)
|Date page was created
|
|
|
|-
|-
Line 35: Line 27:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 45: Line 37:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 69: Line 61:
|-
|-
|    Essential  Thrombocythaemia (ET)||Disease
|    Essential  Thrombocythaemia (ET)||Disease
|Rebecca Smith
|Rebecca Smith (trainee) + Fabiola Quintero-Rivera
|
|
|
|
|complete
|complete/pending faculty review
|
|
|FQR
|FQR
|
|
|8/1/21 FQR deleted "'''This page is under construction'''
|
|-
|-
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
|Chelsea D. Kramish (trainee), Daynna J.Wolff
|(trainee), Daynna J.Wolff
|
|
|
|
|complete/pending faculty review
|pending faculty review
|
|
|FQR
|FQR
Line 90: Line 82:
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
|Thomas Lee
|Thomas Lee
|
|8/17/2020
|
|9/7/2020
|complete
|complete
|
|
Line 98: Line 90:
|
|
|-
|-
|'''''Mastocytosis'''''||'''''Overview'''''||Shashi Shetty, Ph.D.
|'''''Mastocytosis'''''||'''''Overview'''''||'''Shashi Shetty, Ph.D.'''
|
|
|
|
Line 107: Line 99:
|-
|-
|    Cutaneous  Mastocytosis||Disease
|    Cutaneous  Mastocytosis||Disease
|Thuy Phung + Shuo-Shawn Liu (trainee)
|Thuy Phung/Shuo-Shawn Liu
|
|
|
|
|complete
|complete/pending adding content online as of 2/4/21
|
|
|FQR
|FQR
|
|
|8/1/21 FQR deleted "'''This page is under construction'''
|
|-
|-
|    Systemic Mastocytosis||Disease
|    Systemic Mastocytosis||Disease
Line 127: Line 119:
|-
|-
|    Mast Cell Sarcoma||Disease
|    Mast Cell Sarcoma||Disease
|Thuy Phung +Jordan Lowery (trainee)
|Thuy Phung +Jordan Lowery
|
|
|
|
Line 183: Line 175:
|Myeloid/Lymphoid Neoplasms with ETV6-JAK2
|Myeloid/Lymphoid Neoplasms with ETV6-JAK2
|Disease
|Disease
|Lauren R. Crowson-Hindman (trainee) + Daynna J. Wolff
|Lauren R. Crowson (trainee)-Hindman + Daynna J. Wolff
|
|
|
|
Line 194: Line 186:
|Myeloid/Lymphoid Neoplasms with BCR-JAK2
|Myeloid/Lymphoid Neoplasms with BCR-JAK2
|Disease
|Disease
|Lauren R. Crowson-Hindman (trainee) + Daynna J. Wolff
|Lauren R. Crowson (trainee) + Daynna J. Wolff
|
|
|
|
Line 233: Line 225:
|
|
|9/1/20
|9/1/20
|PENDING importing content and reference formatting
|PENDING
|
|
|FQR
|FQR
|
|
|FQR has emailed SR several times, last 4/20/22
|
|-
|-
|     Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts  and Thrombocytosis (MDS/MPN-RS-T)||Disease||Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera
|     Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts  and Thrombocytosis (MDS/MPN-RS-T)||Disease||Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera
Line 245: Line 237:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 257: Line 249:
|
|
|-
|-
|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Jack Reid (trainee)+Fabiola Quintero-Rivera
|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Teresa Smolarek?
|
|
|4/21/22
|9/1/20
|pending
|pending
|
|
Line 295: Line 287:
|    Myelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|    Myelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|
|
|
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 305: Line 297:
|
|
|9/1/20
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 332: Line 324:
|
|
|9/1/20
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 366: Line 358:
|
|
|
|
|''<s>PENDING</s> Complete - awaiting clarification''
|PENDING
| ||JH / MS
| ||JH / MS
|04/26/2021 -MS (re-review)
|04/26/2021 -MS (re-review)
|Review completed, awaiting some clarification from JH - 07/04/2022
|
|-
|-
|    Myeloid Neoplasms with Germline DDX41  Mutation||Disease||Fei Yang
|    Myeloid Neoplasms with Germline DDX41  Mutation||Disease||Fei Yang
Line 476: Line 468:
|
|
|-
|-
|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease||Kay Weng Choy + Greg
|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease||Kay Weng Choy + Greg Conboy (Monash Health)
Corboy (Monash Health)
|
|
|
|
Line 485: Line 476:
|
|
|-
|-
|    Acute Myeloid Leukemia (AML) with  Mutated NPM1||Disease||Xinjie Xu
|    Acute Myeloid Leukemia (AML) with  Mutated NPM1||Disease||Xinjie Xu+Kay Weng Choy + Greg Conboy (Monash Health)
|
|
|
|
Line 493: Line 484:
|Add WHO reference
|Add WHO reference
|-
|-
|    Acute Myeloid Leukemia (AML) with  Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg  Corboy (Monash Health)
|    Acute Myeloid Leukemia (AML) with  Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg  Conboy (Monash Health)
|
|
|
|
Line 711: Line 702:
|Acute  Myeloid Leukemia (AML) with Mutated FLT3
|Acute  Myeloid Leukemia (AML) with Mutated FLT3
|Disease
|Disease
|Kay Weng Choy + Greg Corboy (Monash Health)
|Kay Weng Choy + Greg Conboy (Monash Health)
|
|
|
|
Line 766: Line 757:
|
|
|-
|-
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain (trainee) + Yassmine Akkari
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain + Yassmine Akkari
|
|
|
|
Line 838: Line 829:
|
|
|
|
|Complete
|PENDING
| ||YA
| ||YA
|
|
Line 931: Line 922:
| ||YA
| ||YA
|
|
|2021 template added
|
|-
|-
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang
Line 939: Line 930:
| ||YA
| ||YA
|
|
|2021 template added
|
|-
|-
| || ||
| || ||
Line 973: Line 964:
|SP
|SP
|
|
|2021 template added
|
|-
|-
|B-cell Prolymphocytic Leukemia||Disease||Zejuan Li
|B-cell Prolymphocytic Leukemia||Disease||
|4/28/22
|
|
|
|
|PENDING
|
|
|SP
|SP
|
|
|2021 template added
|
|-
|-
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
Line 1,029: Line 1,020:
|
|
|-
|-
|Lymphoplasmacytic Lymphoma||Disease||Kapitolina Semenova (trainee)+Fabiola Quintero-Rivera
|Lymphoplasmacytic Lymphoma||Disease||
|
|
|
|
|
|PENDING review  by FQR
|
|
|SP
|SP
|
|
|2021 template added
|
|-
|-
|   Waldenstrom  Macroglobulinemia||Disease||Kapitolina Semenova (trainee)+Fabiola Quintero-Rivera
|   Waldenstrom  Macroglobulinemia||Disease||
|
|
|
|
|
|PENDING review  by FQR
|
|
|SP
|SP
|
|
|2021 template added
|
|-
|-
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
Line 1,132: Line 1,123:
|
|
|-
|-
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||Chen Yang, MD, PhD
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||
|
|
|
|
|Complete
|
|09/10/2022||SP
| ||SP
|
|
|
|
|-
|-
|           Primary  Amyloidosis||Disease||Heather E. Williams, PhD
|           Primary  Amyloidosis||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|           Light Chain and Heavy Chain Deposition Disease||Disease||Chen Yang, MD, PhD
|           Light Chain and Heavy Chain Deposition Disease||Disease||
|
|
|
|
|
|Complete
| ||SP
|10/15/2022||SP
|
|
|
|
|-
|-
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||Sohini Anand
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||
|8/31/2021
|
|9/15/2021
|
|PENDING
|
| ||SP
| ||SP
|
|
|
|
|-
|-
|         POEMS Syndrome||Disease||Sohini Anand, MBBS, and Tharanga Niroshini Senaratne, PhD
|         POEMS Syndrome||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|         TEMPI Syndrome||Disease||Sohini Anand, MBBS
|         TEMPI Syndrome||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee (trainee)/Fabiola Quintero-Rivera
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee, trainee)/Fabiola Quintero-Rivera
|3/9/21
|3/9/21
|
|
Line 1,187: Line 1,178:
|SP
|SP
|
|
|2021 template added
|
|-
|-
|Nodal Marginal Zone Lymphoma||Disease||Shivani Golem
|Nodal Marginal Zone Lymphoma||Disease||Shivani Golem
Line 1,197: Line 1,188:
|
|
|-
|-
|    Paediatric Nodal Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
|    Paediatric Nodal Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
|
|
|
|
Line 1,215: Line 1,206:
|
|
|-
|-
|    Testicular Follicular Lymphoma||Disease||Ruthann Pfau
|    Testicular Follicular Lymphoma||Disease||Ruthann Pfau
|
|
|
|
Line 1,224: Line 1,215:
|
|
|-
|-
|    In Situ Follicular Neoplasia||Disease||Ruthann Pfau
|    In Situ Follicular Neoplasia||Disease||Ruthann Pfau
|
|
|
|
Line 1,233: Line 1,224:
|
|
|-
|-
|    Duodenal-Type Follicular Lymphoma||Disease||Ruthann Pfau
|    Duodenal-Type Follicular Lymphoma||Disease||Ruthann Pfau
|
|
|
|
Line 1,262: Line 1,253:
|
|
|
|
|Complete
|PENDING
|09/10/2022
| ||SP
|SP
|
|
|
|
Line 1,277: Line 1,267:
|
|
|-
|-
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||Tsigab Hagos (trainee)/Shashirekha.Shetty
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||
|12/19/2022
|
|1/19/2022
|
|Pending
|
|
|
|SP
|SP
Line 1,286: Line 1,276:
|
|
|-
|-
|    In Situ Mantle Cell  Neoplasia||Disease||Rina Kansal, MD
|    In Situ Mantle Cell  Neoplasia||Disease||
|6/12/22
|
|
|
|
|
|Complete
|7/26/2022
|SP
|SP
|
|
|2021 template added
|
|-
|-
| || ||
| || ||
Line 1,310: Line 1,300:
|Greg Corboy (GC)
|Greg Corboy (GC)
|
|
|Requested to update 14022022
|
|-
|-
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
Line 1,320: Line 1,310:
|
|
|-
|-
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||Laveniya Satgunaseelan
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||
|26/10/2021
|
|26/1/2022
|
|Complete
|
|03/28/22||GC
| ||GC
|03/28/22
|
|2021 template added
|
|-
|-
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
Line 1,384: Line 1,374:
|
|
|-
|-
|Intravascular Large B-cell Lymphoma||Disease||Kate Berry, Greg Corboy
|Intravascular Large B-cell Lymphoma||Disease||
|25/01/2022
|
|25/4/2022
|
|Complete
|
|9/1/22||GC
| ||GC
|9/1/22
|
|Emailed 28/3/2022 for progress update
|
|-
|-
|ALK-Positive Large B-cell Lymphoma||Disease||Nakasaki Manando
|ALK-Positive Large B-cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||GC
| ||GC
|
|
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note).  2021 template added.
|
|-
|-
|Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera
|Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera
Line 1,405: Line 1,395:
|Complete
|Complete
| ||GC
| ||GC
|28/03/2022
|
|
|
|-
|-
Line 1,424: Line 1,414:
|
|
|-
|-
|   Multicentric Castleman  Disease||Disease||Sudha Arumugam
|   Multicentric Castleman  Disease||Disease||
|10/26/2021
|
|1/26/2022
|
|Complete
|
|24/01/2022||GC
|24/01/2022
|2021 template added
|-
|   HHV8-Positive Diffuse  Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Xiao Zhou, MD, PhD, Siparadigm
|10/26/2021
|1/26/2022
|PENDING
| ||GC
| ||GC
|
|
|Emailed 28/3/2022 for progress update
|
|-
|-
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||Xiao Zhou, MD, PhD, Siparadigm
|   HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
|10/26/2021
|
|1/26/2022
|
|PENDING
|
| ||GC
| ||GC
|
|
|Emailed 28/3/2022 for progress update
|-
|Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy
|3/11/21
|06/28/2021
|Complete
|28/06/2021||GC
|28/06/2021
|
|
|-
|-
|Burkitt-Like Lymphoma with 11q Aberration||Disease||Lauren Shealy (trainee), Daynna Wolff
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||
|10/13/21
|01/13/2022
|Complete
|27/01/2022
|GC
|27/01/2021
|2021 template added
|-
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
|
|
|
|
Line 1,473: Line 1,438:
|
|
|-
|-
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||Kate Berry, Greg Corboy
|Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy
|30/05/21
|3/11/21
|30/08/21
|
|Complete
|PENDING
|24/02/2022||GC
| ||GC
|24/02/2022
|
|
|-
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||Aiko Otsubo, Holli Drendel
|7/30/21
|10/30/21
|Complete
|15/11/2021
|GC
|16/11/2021
|
|
|-
|-
|B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
|Burkitt-Like Lymphoma with 11q Aberration||Disease||
|
|
|
|
Line 1,498: Line 1,454:
|
|
|-
|-
| || ||
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
|
|
|
| ||GC
|
|
|-
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||
|
|
|
| ||GC
|
|
|-
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||
|
|
|
| ||GC
|
|
|-
|B-cell Lymphoma, Unclassifiable, with Features Intermediate  Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
|
|
|
| ||GC
|
|
|-
| || ||
|
|
|
|
Line 1,538: Line 1,526:
|
|
|-
|-
|Aggressive NK-cell Leukemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD
|Aggressive NK-cell Leukemia||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
Line 1,557: Line 1,545:
|
|
|
|
|Complete
|PENDING
|11/21/2021||SP
| ||SP
|
|
|
|
Line 1,570: Line 1,558:
|
|
|-
|-
|    Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease||
|    Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease||
|
|
|
|
Line 1,586: Line 1,574:
|
|
|-
|-
|Adult T-cell Leukemia/Lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG
|Adult T-cell Leukemia/Lymphoma||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
Line 1,605: Line 1,593:
|
|
|
|
|Complete
|PENDING
|9/26/2022
|
|SP
|SP
|
|
Line 1,632: Line 1,620:
|
|
|
|
|Complete
|PENDING
|9/26/2022
|
|SP
|SP
|
|
Line 1,672: Line 1,660:
|
|
|-
|-
|Sézary Syndrome||Disease||Daynna Wolff, Madison Hannay (trainee), Tingting Barrett (trainee)
|Sézary Syndrome||Disease||Daynna Wolff, Madison Hannay (trainee)
|
|
|
|
Line 1,680: Line 1,668:
|
|
|-
|-
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||Peining Li, PhD
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|    Lymphomatoid  Papulosis||Disease||Peining Li, PhD
|    Lymphomatoid  Papulosis||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|    Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD
|    Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||Peining Li, PhD
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||Peining Li, PhD
|     Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||Peining Li, PhD
|     Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||Peining Li, PhD
|     Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||Peining Li, PhD
|     Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
Line 1,786: Line 1,774:
|
|
|-
|-
|Anaplastic Large Cell Lymphoma, ALK-Positive||Disease||Sumire Kitahara / Miguel Gonzalez (trainee)
|Anaplastic Large Cell Lymphoma, ALK-Positive||Disease||Sumire Kitahara
|
|
|
|
|Completed
|PENDING
|09/23/2022
|
|SP
|SP
|
|
|
|
|-
|-
|Anaplastic Large Cell Lymphoma, ALK-Negative||Disease||Sumire Kitahara / Miguel Gonzalez (trainee)
|Anaplastic Large Cell Lymphoma, ALK-Negative||Disease||Sumire Kitahara
|
|
|
|
|Completed
|PENDING
|09/23/2022
|
|SP
|SP
|
|
Line 1,829: Line 1,817:
|
|
|-
|-
|Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease||Thomas Harrington (resident) + Daynna Wolff
|Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease||
|06/22/2022
|
|09/22/2022
|
|PENDING
|
| ||GC
| ||GC
|
|
|2021 template added, Daynna organising
|
|-
|-
|'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''||
|'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''||
Line 1,845: Line 1,833:
|
|
|-
|-
|    Nodular Sclerosis  Classic Hodgkin Lymphoma||Disease||Xiaolin (Lynn) Hu
|    Nodular Sclerosis  Classic Hodgkin Lymphoma||Disease||
|
|
|
|
|Completed
|03/21/22||GC
|03/21/22
|Edits sent 14022022
|-
|    Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|
|
| ||GC
|
|
|PENDING
| ||GC
|
|
|2021 template added
|-
|-
|    Mixed Cellularity Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|    Lymphocyte-Rich  Classic Hodgkin Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|    Lymphocyte-Depleted Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|    Mixed Cellularity Classic Hodgkin Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
|    Lymphocyte-Depleted  Classic Hodgkin Lymphoma||Disease||
|
|
|
|
Line 1,885: Line 1,865:
|
|
|-
|-
|Lymphomas Associated with HIV Infection||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
|11/2/21
|
|02/02/22
|
|Completed
|
|03/21/22
| ||GC
|GC
|
|03/21/22
|
|2021 template added
|-
|Lymphomas Associated with HIV Infection||Disease||
|
|
|
| ||GC
|
|
|-
|-
|'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''||
|'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''||
Line 1,910: Line 1,897:
|
|
|-
|-
|    Polymorphic  Post-Transplant Lymphoproliferative Disorders||Disease||Ania Shestakova (trainee) + Fabiola Quintero-Rivera
|    Polymorphic  Post-Transplant Lymphoproliferative Disorders||Disease||Anna Shestakova (trainee)''+,''
 
Fabiola Quintero-Rivera
|
|
|
|PENDING
|
|
|completed
|april 2022
|GC
|GC
|26/4/2022
|
|
|
|-
|-
Line 1,967: Line 1,956:
|
|
|-
|-
|Histiocytic Sarcoma||Disease||Marie-France Gagnon, MD, Mayo Clinic (LGG fellow trainee), Xinjie Xu, PhD FACMG, Mayo Clinic
|Histiocytic Sarcoma||Disease||
|
|
|
| ||GC
|
|
|
|
|Complete
|10/01/2021
|GC
|10/01/2021
|Xinjie Xu
|-
|-
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
Line 1,984: Line 1,972:
|
|
|-
|-
|   Langerhans Cell  Histiocytosis||Disease||Malaika Perchard, Greg Corboy
|   Langerhans Cell  Histiocytosis||Disease||
|02/01/2022
|
|05/01/2022
|
|Complete
|
|04/28/2022||GC
| ||GC
|5/19/2022
|
|
|
|-
|-
|   Langerhans Cell  Sarcoma||Disease||Malaika Perchard, Greg Corboy
|   Langerhans Cell  Sarcoma||Disease||
|02/01/2022
|
|05/01/2022
|
|Complete
|
|04/28/2022||GC
| ||GC
|5/19/2022
|
|
|
|-
|-
Line 2,048: Line 2,036:
|
|
|-
|-
|Erdheim-Chester Disease||Disease||Prashant Deshpande
|Erdheim-Chester Disease||Disease||
|02/02/2022
|
|05/02/2022
|
|PENDING
|
| ||GC
| ||GC
|
|
|
|emailed 28/3/2022 to get update
|-
|-
| || ||
| || ||
Line 2,215: Line 2,203:
|
|
|
|
|}<br />
|}
 
{| class="wikitable sortable"
==WHO Classification of Tumours of the Central Nervous System Content==
|+Gene-Specific Pages
{| class="wikitable"
!'''Gene'''
|-
!'''Author'''
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Date Assigned to Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Date of Last Editor Review'''
!'''Notes'''
!'''Notes'''
|-
|-
|Medulloblastoma, WNT-activated||Disease||Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|BCR
|9/20/21
|Brian Davis
|
|
|COMPLETE
|
|
|Holli Drendel (interim)/Laveniya Satgunaseelan (LS)
|Complete
|9/22/2022
|8/10/18
|2021 template added
|
|-
|Paediatric-Type Diffuse High-Grade Gliomas
|Overview
|
|
|
|
|-
|ABL1
|Brian Davis
|
|
|
|
|Complete
|4/16/19
|
|
|
|
|
|
|2021 template added
|-
|-
|Diffuse Midline Glioma, H3 K27-Altered
|RUNX1
|Disease
|Brian Davis
|Laveniya Satgunaseelan (Linda Cooley - previous version)
|
|
|
|
|PENDING
|Complete
|6/9/19
|
|
|
|Laveniya Satgunaseelan (LS)
|
|
|2021 template added
|-
|-
|Diffuse Hemispheric Glioma, H3 G34-Mutant
|RUNX1T1
|Disease
|Brian Davis
|Xiaolin (Lynn) Hu
|
|2/21/2022
|
|Complete
|5/23/19
|
|
|PENDING
|
|
|LS
|
|
|2021 template added
|-
|-
|Diffuse Paediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype
|MYH11
|Disease
|Brian Davis
|Madina Sukhanova
|
|10/28/2022
|
|Complete
|8/6/18
|
|
|PENDING
|
|
|LS
|
|
|2021 template added
|-
|-
|Infant-Type Hemispheric Glioma
|FLT3
|Disease
|Kay Weng Choy
|
|
|Complete
|
|
|
|
|
|
|
|-
|NPM1
|Kay Weng Choy
|
|
|Complete
|
|
|
|
|
|
|
|
|2021 template added
|-
|-
|Astrocytoma, IDH-Mutant
|TP53
|Disease
|Kay Weng Choy
|Riley Lochner (trainee), Shashi Shetty (mentor)
|3/3/2022
|
|
|PENDING
|
|
|LS
|Complete
|
|
|2021 template added
|-
|Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
|Disease
|Riley Lochner (trainee), Shashi Shetty (mentor)
|3/3/2022
|
|
|PENDING
|
|
|LS
|
|
|2021 template added
|-
|-
|Ganglioglioma
|DNMT3A
|Disease
|Kay Weng Choy
|Leila Moayed-Aloei
|6/30/2022
|
|
|COMPLETE
|
|
|LS
|Complete
|
|
|2021 template added
|-
|Pilocytic Astrocytoma
|Disease
|Jeremy Pulvers
|9/13/2022
|
|
|PENDING
|
|
|LS
|
|
|2021 template added
|-
|-
|}<br />
|CEBPA
 
|Gordana
==WHO Classification of Soft Tissue and Bone Tumours Content==
|
{| class="wikitable"
|
|-
|Complete
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|NTRK-Rearranged Spindle Cell Neoplasm||Disease||James Solomon, MD, PhD
|2/20/2022
|
|
|PENDING
|
|
|Alanna Church
|
|
|
|
|-
|-
|}<br />
|IDH1
 
|Paul De Fazio
==WHO Classification of Tumours of Breast Tumours Content==
{| class="wikitable"
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|Adenoid Cystic Carcinoma
|Disease||Katherine Geiersbach
|10/12/02022
|
|
|PENDING
|
|
|Hui Chen
|Complete
|
|
|2021 template added
|-
|Secretory Carcinoma
|Disease
|Hui Chen
|10/12/2022
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|2021 template added
|-
|-
|}<br />
|IDH2
 
|Paul De Fazio
==Gene-Specific Pages (IN PROCESS OF AUTOMATING - HOLD ON VOLUNTEERING)==
|
{| class="wikitable sortable"
!'''Gene'''
!'''Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|BCR
|Brian Davis
|
|
|Complete
|
|
|Complete
|8/10/18
|
|
|
|
|
|
|-
|-
|ABL1
|PML
|Brian Davis
|Brian Davis
|
|
|
|
|Complete
|Complete
|4/16/19
|12/5/18
|
|
|
|
|
|
|-
|-
|RUNX1
|RARA
|Brian Davis
|Brian Davis
|
|
|
|
|Complete
|Complete
|6/9/19
|8/3/18
|
|
|
|
|
|
|-
|-
|RUNX1T1
|ETV6
|Brian Davis
|Brian Davis
|
|
|
|
|Complete
|Complete
|5/23/19
|6/9/19
|
|
|
|
|
|
|-
|-
|MYH11
|KIT
|Brian Davis
|Brian Davis
|
|
|
|
|Complete
|Complete
|8/6/18
|10/1/18
|
|
|
|
|
|
|-
|-
|FLT3
|CBFB
|Kay Weng Choy
|Brian Davis
|
|
|
|
|Complete
|Complete
|
|8/2/18
|
|
|
|
|
|
|-
|-
|NPM1
|GATA2
|Kay Weng Choy
|Kay Weng Choy
|
|
Line 2,476: Line 2,396:
|
|
|-
|-
|TP53
|PTEN
|Kay Weng Choy
|Beth Pitel
|
|
|
|
|Complete
|Pending
|
|
|
|
Line 2,486: Line 2,406:
|
|
|-
|-
|DNMT3A
|MLTT3
|Kay Weng Choy
|
|
|
|
|
|
|Complete
|
|
|
|
Line 2,496: Line 2,416:
|
|
|-
|-
|CEBPA
|MECOM
|Gordana
|Brian Davis
|
|
|
|
|Complete
|Pending
|
|
|
|
Line 2,506: Line 2,426:
|
|
|-
|-
|IDH1
|FGFR1(FLT2)
|Paul De Fazio
|Brian Davis
|
|
|
|
|Complete
|Pending
|
|
|
|
Line 2,516: Line 2,436:
|
|
|-
|-
|IDH2
|KMT2A
|Paul De Fazio
|
|
|
|
|
|
|Complete
|
|
|
|
Line 2,526: Line 2,446:
|
|
|-
|-
|PML
|DEK
|Brian Davis
|Wahab A. Khan
|
|
|
|
|Complete
|Pending
|12/5/18
|
|
|
|
|
|
|
|-
|-
|RARA
|NUP214
|Brian Davis
|Wahab A. Khan
|
|
|
|Pending
|
|
|Complete
|8/3/18
|
|
|
|
|
|
|-
|-
|ETV6
|RBM15
|Brian Davis
|
|
|
|
|Complete
|6/9/19
|
|
|
|
|
|
|-
|KIT
|Brian Davis
|
|
|Complete
|10/1/18
|
|
|
|
|
|
|-
|-
|CBFB
|MKL1
|Brian Davis
|
|
|Complete
|8/2/18
|
|
|
|
|
|
|-
|GATA2
|Kay Weng Choy
|
|
|
|Complete
|
|
|
|
Line 2,586: Line 2,486:
|
|
|-
|-
|PTEN
|DDX41
|Beth Pitel
|Ying Zou
|
|8/7/20
|
|
|Pending
|Pending
Line 2,596: Line 2,496:
|
|
|-
|-
|MLTT3
|ANKRD26
|
|
|
|
Line 2,606: Line 2,506:
|
|
|-
|-
|MECOM
|CUX1
|Brian Davis
|
|
|
|
|Pending
|
|
|
|
|
|
|
|
|-
|FGFR1(FLT2)
|Brian Davis
|
|
|
|
|Pending
|-
|TET2
|
|
|
|
|
|
|
|
|-
|KMT2A
|
|
|
|
|
|
|
|
|-
|EZH2
|
|
|
|
|
|
|
|
|-
|DEK
|Wahab A. Khan
|
|
|
|
|Pending
|
|
|
|
|-
|FOXP1
|
|
|
|
|-
|NUP214
|Wahab A. Khan
|
|
|
|
|Pending
|
|
|
|
Line 2,656: Line 2,546:
|
|
|-
|-
|RBM15
|MYC
|
|
|
|
Line 2,666: Line 2,556:
|
|
|-
|-
|MKL1
|JAK2
|
|
|
|
Line 2,676: Line 2,566:
|
|
|-
|-
|DDX41
|WT1
|Ying Zou
|DONE
|8/7/20
|
|
|
|Pending
|DONE
|
|
|
|
Line 2,686: Line 2,576:
|
|
|-
|-
|ANKRD26
|CBL
|
|
|
|
Line 2,696: Line 2,586:
|
|
|-
|-
|CUX1
|NF1
|
|
|
|
Line 2,706: Line 2,596:
|
|
|-
|-
|TET2
|SUZ12
|
|
|
|
Line 2,716: Line 2,606:
|
|
|-
|-
|EZH2
|ERG
|
|
|
|
Line 2,726: Line 2,616:
|
|
|-
|-
|FOXP1
|EST2
|
|
|
|
Line 2,736: Line 2,626:
|
|
|-
|-
|MYC
|RPS14
|
|
|
|
Line 2,746: Line 2,636:
|
|
|-
|-
|JAK2
|RB1
|
|
|
|
Line 2,756: Line 2,646:
|
|
|-
|-
|WT1
|MPL
|DONE
|
|
|
|
|
|
|DONE
|
|
|
|
Line 2,766: Line 2,656:
|
|
|-
|-
|CBL
|CHGA
|
|
|
|
Line 2,776: Line 2,666:
|
|
|-
|-
|NF1
|CDH1
|
|
|
|
Line 2,786: Line 2,676:
|
|
|-
|-
|SUZ12
|SRSF2
|
|
|
|
Line 2,796: Line 2,686:
|
|
|-
|-
|ERG
|DNMT1
|
|
|
|
Line 2,806: Line 2,696:
|
|
|-
|-
|EST2
|PRDX2
|
|
|
|
Line 2,816: Line 2,706:
|
|
|-
|-
|RPS14
|ASXL1
|
|DONE
|
|
|
|
|
|DONE
|
|
|
|
Line 2,826: Line 2,716:
|
|
|-
|-
|RB1
|MN1
|
|
|
|
Line 2,836: Line 2,726:
|
|
|-
|-
|MPL
|SF3A1
|
|
|
|
Line 2,846: Line 2,736:
|
|
|-
|-
|CHGA
|EP300
|
|
|
|
Line 2,856: Line 2,746:
|
|
|-
|-
|CDH1
|JARID2
|
|
|
|
Line 2,866: Line 2,756:
|
|
|-
|-
|SRSF2
|BRCA1
|
|
|
|
Line 2,876: Line 2,766:
|
|
|-
|-
|DNMT1
|BRCA2
|
|
|
|
|
|
|
|
|-
|PRDX2
|
|
|
|
|
|
|
|
|-
|ASXL1
|DONE
|
|
|DONE
|
|
|
|
|-
|MN1
|
|
|
|
|
|
|
|
|-
|SF3A1
|
|
|
|
|
|
|
|
|-
|EP300
|
|
|
|
|
|
|
|
|-
|JARID2
|
|
|
|
|
|
|
|
|-
|BRCA1
|
|
|
|
|
|
|
|
|-
|BRCA2
|
|
|
|
|
|
|
|
|-
|
|
|
|
|
|
|
|
|
|-
|
|
|
|
|
|
|
|
|
|}
 
==WHO Central Nervous System Tumours  (5th ed.) Content==
{| class="wikitable"
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|- |Astrocytoma, IDH-mutant||Disease||
|
|
|
|
|
|
|
|-
|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted||Disease||
|
|
|
|
|
|
|
|-
|Glioblastoma, IDH-wildtype||Disease||
|
|
|
|
|
|
|
|-
|Diffuse astrocytoma, MYB- or MYBL1-altered||Disease||
|
|
|
|
|
|
|
|-
|Angiocentric glioma||Disease||
|
|
|
|
|
|
|
|-
|Polymorphous low-grade neuroepithelial tumour of the young||Disease||
|
|
|
|
|
|
|
|-
|Diffuse low-grade glioma, MAPK pathway-altered||Disease||
|
|
|
|
|
|
|
|-
|Diffuse midline glioma, H3 K27-altered||Disease||
|
|
|
|
|
|
|
|-
|Diffuse hemispheric glioma, H3 G34-mutant||Disease||
|
|
|
|
|
|
|
|-
|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype||Disease||
|
|
|
|
|
|
|
|-
|Infant-type hemispheric glioma||Disease||
|
|
|
|
|
|
|
|-
|Pilocytic astrocytoma||Disease||
|
|
|
|
|
|
|
|-
|High-grade astrocytoma with piloid features||Disease||
|
|
|
|
|
|
|
|-
|Pleomorphic xanthoastrocytoma||Disease||
|
|
|
|
|
|
|
|-
|Subependymal giant cell astrocytoma||Disease||
|
|
|
|
|
|
|
|-
|Chordoid glioma||Disease||
|
|
|
|
|
|
|
|-
|Astroblastoma, MN1-altered||Disease||
|
|
|
|
|
|
|
|-
|Ganglioglioma||Disease||
|
|
|
|
|
|
|
|-
|Gangliocytoma||Disease||
|
|
|
|
|
|
|
|-
|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma||Disease||
|
|
|
|
|
|
|
|-
|Dysembryoplastic neuroepithelial tumour||Disease||
|
|
|
|
|
|
|
|-
|Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters||Disease||
|
|
|
|
|
|
|
|-
|Papillary glioneuronal tumour||Disease||
|
|
|
|
|
|
|
|-
|Rosette-forming glioneuronal tumour||Disease||
|
|
|
|
|
|
|
|-
|Myxoid glioneuronal tumour||Disease||
|
|
|
|
|
|
|
|-
|Diffuse leptomeningeal glioneuronal tumour||Disease||
|
|
|
|
|
|
|
|-
|Multinodular and vacuolating neuronal tumour||Disease||
|
|
|
|
|
|
|
|-
|Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease)||Disease||
|
|
|
|
|
|
|
|-
|Central neurocytoma||Disease||
|
|
|
|
|
|
|
|-
|Extraventricular neurocytoma||Disease||
|
|
|
|
|
|
|
|-
|Cerebellar liponeurocytoma||Disease||
|
|
|
|
|
|
|
|-
|Supratentorial ependymoma||Disease||
|
|
|
|
|
|
|
|-
|Supratentorial ependymoma, ZFTA fusion-positive||Disease||
|
|
|
|
|
|
|
|-
|Supratentorial ependymoma, YAP1 fusion-positive||Disease||
|
|
|
|
|
|
|
|-
|Posterior fossa ependymoma||Disease||
|
|
|
|
|
|
|
|-
|Posterior fossa group A (PFA) ependymoma||Disease||
|
|
|
|
|
|
|
|-
|Posterior fossa group B (PFB) ependymoma||Disease||
|
|
|
|
|
|
|
|-
|Spinal ependymoma||Disease||
|
|
|
|
|
|
|
|-
|Spinal ependymoma, MYCN-amplified||Disease||
|
|
|
|
|
|
|
|-
|Myxopapillary ependymoma||Disease||
|
|
|
|
|
|
|
|-
|Subependymoma||Disease||
|
|
|
|
|
|
|
|-
|Choroid plexus papilloma||Disease||
|
|
|
|
|
|
|
|-
|Atypical choroid plexus papilloma||Disease||
|
|
|
|
|
|
|
|-
|Choroid plexus carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Medulloblastoma, WNT-activated||Disease||
|
|
|
|
|
|
|
|-
|Medulloblastoma, SHH-activated and TP53-wildtype||Disease||
|
|
|
|
|
|
|
|-
|Medulloblastoma, SHH-activated and TP53-mutant||Disease||
|
|
|
|
|
|
|
|-
|Medulloblastoma, non-WNT/non-SHH||Disease||
|
|
|
|
|
|
|
|-
|Medulloblastoma, histologically defined||Disease||
|
|
|
|
|
|
|
|-
|Atypical teratoid/rhabdoid tumour||Disease||
|
|
|
|
|
|
|
|-
|Cribriform neuroepithelial tumour||Disease||
|
|
|
|
|
|
|
|-
|Embryonal tumour with multilayered rosettes||Disease||
|
|
|
|
|
|
|
|-
|CNS neuroblastoma, FOXR2-activated||Disease||
|
|
|
|
|
|
|
|-
|CNS tumour with BCOR internal tandem duplication||Disease||
|
|
|
|
|
|
|
|-
|CNS embryonal tumour NEC/NOS||Disease||
|
|
|
|
|
|
|
|-
|Pineocytoma||Disease||
|
|
|
|
|
|
|
|-
|Pineal parenchymal tumour of intermediate differentiation||Disease||
|
|
|
|
|
|
|
|-
|Pineoblastoma||Disease||
|
|
|
|
|
|
|
|-
|Papillary tumour of the pineal region||Disease||
|
|
|
|
|
|
|
|-
|Desmoplastic myxoid tumour of the pineal region, SMARCB1-mutant||Disease||
|
|
|
|
|
|
|
|-
|Schwannoma||Disease||
|
|
|
|
|
|
|
|-
|Neurofibroma||Disease||
|
|
|
|
|
|
|
|-
|Perineurioma||Disease||
|
|
|
|
|
|
|
|-
|Hybrid nerve sheath tumours||Disease||
|
|
|
|
|
|
|
|-
|Malignant melanotic nerve sheath tumour||Disease||
|
|
|
|
|
|
|
|-
|Malignant peripheral nerve sheath tumour||Disease||
|
|
|
|
|
|
|
|-
|Cauda equina neuroendocrine tumour (previously paraganglioma)||Disease||
|
|
|
|
|
|
|
|-
|Meningioma||Disease||
|
|
|
|
|
|
|
|-
|Solitary fibrous tumour||Disease||
|
|
|
|
|
|
|
|-
|Haemangiomas and vascular malformations||Disease||
|
|
|
|
|
|
|
|-
|Haemangioblastoma||Disease||
|
|
|
|
|
|
|
|-
|Rhabdomyosarcoma||Disease||
|
|
|
|
|
|
|
|-
|Intracranial mesenchymal tumour, FET::CREB fusion-positive||Disease||
|
|
|
|
|
|
|
|-
|CIC-rearranged sarcoma||Disease||
|
|
|
|
|
|
|
|-
|Primary intracranial sarcoma, DICER1-mutant||Disease||
|
|
|
|
|
|
|
|-
|Ewing sarcoma||Disease||
|
|
|
|
|
|
|
|-
|Mesenchymal chondrosarcoma||Disease||
|
|
|
|
|
|
|
|-
|Chondrosarcoma||Disease||
|
|
|
|
|
|
|
|-
|Chordoma||Disease||
|
|
|
|
|
|
|
|-
|Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis||Disease||
|
|
|
|
|
|
|
|-
|Circumscribed meningeal melanocytic neoplasms: Melanocytoma and melanoma||Disease||
|
|
|
|
|
|
|
|-
|Primary diffuse large B-cell lymphoma of the CNS||Disease||
|
|
|
|
|
|
|
|-
|Immunodeficiency-associated CNS lymphomas||Disease||
|
|
|
|
|
|
|
|-
|Lymphomatoid granulomatosis||Disease||
|
|
|
|
|
|
|
|-
|Intravascular large B-cell lymphoma||Disease||
|
|
|
|
|
|
|
|-
|MALT lymphoma of the dura||Disease||
|
|
|
|
|
|
|
|-
|Other low-grade B-cell lymphomas of the CNS||Disease||
|
|
|
|
|
|
|
|-
|Anaplastic large cell lymphoma (ALK+/ALK−)||Disease||
|
|
|
|
|
|
|
|-
|T-cell and NK/T-cell lymphomas||Disease||
|
|
|
|
|
|
|
|-
|Erdheim-Chester disease||Disease||
|
|
|
|
|
|
|
|-
|Rosai-Dorfman disease||Disease||
|
|
|
|
|
|
|
|-
|Juvenile xanthogranuloma||Disease||
|
|
|
|
|
|
|
|-
|Langerhans cell histiocytosis||Disease||
|
|
|
|
|
|
|
|-
|Histiocytic sarcoma||Disease||
|
|
|
|
|
|
|
|-
|Germ cell tumours of the CNS||Disease||
|
|
|
|
|
|
|
|-
|Adamantinomatous craniopharyngioma||Disease||
|
|
|
|
|
|
|
|-
|Papillary craniopharyngioma||Disease||
|
|
|
|
|
|
|
|-
|Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma||Disease||
|
|
|
|
|
|
|
|-
|Pituitary adenoma / pituitary neuroendocrine tumour||Disease||
|
|
|
|
|
|
|
|-
|Pituitary blastoma||Disease||
|
|
|
|
|
|
|
|-
|Metastases to the brain and spinal cord parenchyma||Disease||
|
|
|
|
|
|
|
|-
|Metastases to the meninges||Disease||
|
|
|
|
|
|
|
|-
|Neurofibromatosis type 1||Disease||
|
|
|
|
|
|
|
|-
|Neurofibromatosis type 2||Disease||
|
|
|
|
|
|
|
|-
|Schwannomatosis||Disease||
|
|
|
|
|
|
|
|-
|Von Hippel-Lindau syndrome||Disease||
|
|
|
|
|
|
|
|-
|Tuberous sclerosis||Disease||
|
|
|
|
|
|
|
|-
|Li-Fraumeni syndrome||Disease||
|
|
|
|
|
|
|
|-
|Cowden syndrome||Disease||
|
|
|
|
|
|
|
|-
|Constitutional mismatch repair deficiency syndrome||Disease||
|
|
|
|
|
|
|
|-
|Familial adenomatous polyposis 1||Disease||
|
|
|
|
|
|
|
|-
|Naevoid basal cell carcinoma syndrome||Disease||
|
|
|
|
|
|
|
|-
|Rhabdoid tumour predisposition syndrome||Disease||
|
|
|
|
|
|
|
|-
|Carney complex||Disease||
|
|
|
|
|
|
|
|-
|DICER1 syndrome||Disease||
|
|
|
|
|
|
|
|-
|Familial paraganglioma syndromes||Disease||
|
|
|
|
|
|
|
|-
|Melanoma-astrocytoma syndrome||Disease||
|
|
|
|
|
|
|
|-
|Familial retinoblastoma||Disease||
|
|
|
|
|
|
|
|-
|BAP1 tumour predisposition syndrome||Disease||
|
|
|
|
|
|
|
|-
|Fanconi anaemia||Disease||
|
|
|
|
|
|
|
|-
|ELP1-medulloblastoma syndrome||Disease||
|
|
|
|
|
|
|
|-
|}
 
==WHO Breast tumours  (5th ed.) Content==
{| class="wikitable"
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|- |Usual ductal hyperplasia||Disease||
|
|
|
|
|
|
|
|-
|Columnar cell lesions, including flat epithelial atypia||Disease||
|
|
|
|
|
|
|
|-
|Atypical ductal hyperplasia||Disease||
|
|
|
|
|
|
|
|-
|Sclerosing adenosis||Disease||
|
|
|
|
|
|
|
|-
|Apocrine adenosis and adenoma||Disease||
|
|
|
|
|
|
|
|-
|Microglandular adenosis||Disease||
|
|
|
|
|
|
|
|-
|Radial scar / complex sclerosing lesion||Disease||
|
|
|
|
|
|
|
|-
|Tubular adenoma||Disease||
|
|
|
|
|
|
|
|-
|Lactating adenoma||Disease||
|
|
|
|
|
|
|
|-
|Ductal adenoma||Disease||
|
|
|
|
|
|
|
|-
|Pleomorphic adenoma||Disease||
|
|
|
|
|
|
|
|-
|Adenomyoepithelioma||Disease||
|
|
|
|
|
|
|
|-
|Malignant adenomyoepithelioma||Disease||
|
|
|
|
|
|
|
|-
|Intraductal papilloma||Disease||
|
|
|
|
|
|
|
|-
|Papillary ductal carcinoma in situ||Disease||
|
|
|
|
|
|
|
|-
|Encapsulated papillary carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Solid papillary carcinoma (in situ and invasive)||Disease||
|
|
|
|
|
|
|
|-
|Invasive papillary carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Atypical lobular hyperplasia||Disease||
|
|
|
|
|
|
|
|-
|Lobular carcinoma in situ||Disease||
|
|
|
|
|
|
|
|-
|Ductal carcinoma in situ||Disease||
|
|
|
|
|
|
|
|-
|Invasive breast carcinoma: General overview||Disease||
|
|
|
|
|
|
|
|-
|Invasive breast carcinoma of no special type||Disease||
|
|
|
|
|
|
|
|-
|Microinvasive carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Invasive lobular carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Tubular carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Cribriform carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Mucinous carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Mucinous cystadenocarcinoma||Disease||
|
|
|
|
|
|
|
|-
|Invasive micropapillary carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Carcinoma with apocrine differentiation||Disease||
|
|
|
|
|
|
|
|-
|Metaplastic carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Acinic cell carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Adenoid cystic carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Secretory carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Mucoepidermoid carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Polymorphous adenocarcinoma||Disease||
|
|
|
|
|
|
|
|-
|Tall cell carcinoma with reversed polarity||Disease||
|
|
|
|
|
|
|
|-
|Neuroendocrine tumour||Disease||
|
|
|
|
|
|
|
|-
|Neuroendocrine carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Hamartoma||Disease||
|
|
|
|
|
|
|
|-
|Fibroadenoma||Disease||
|
|
|
|
|
|
|
|-
|Phyllodes tumour||Disease||
|
|
|
|
|
|
|
|-
|Syringomatous tumour||Disease||
|
|
|
|
|
|
|
|-
|Nipple adenoma||Disease||
|
|
|
|
|
|
|
|-
|Paget disease of the breast||Disease||
|
|
|
|
|
|
|
|-
|Haemangioma||Disease||
|
|
|
|
|
|
|
|-
|Angiomatosis||Disease||
|
|
|
|
|
|
|
|-
|Atypical vascular lesions||Disease||
|
|
|
|
|
|
|
|-
|Postradiation angiosarcoma of the breast||Disease||
|
|
|
|
|
|
|
|-
|Primary angiosarcoma of the breast||Disease||
|
|
|
|
|
|
|
|-
|Nodular fasciitis||Disease||
|
|
|
|
|
|
|
|-
|Myofibroblastoma||Disease||
|
|
|
|
|
|
|
|-
|Desmoid fibromatosis||Disease||
|
|
|
|
|
|
|
|-
|Inflammatory myofibroblastic tumour||Disease||
|
|
|
|
|
|
|
|-
|Schwannoma||Disease||
|
|
|
|
|
|
|
|-
|Neurofibroma||Disease||
|
|
|
|
|
|
|
|-
|Granular cell tumour||Disease||
|
|
|
|
|
|
|
|-
|Leiomyoma||Disease||
|
|
|
|
|
|
|
|-
|Leiomyosarcoma||Disease||
|
|
|
|
|
|
|
|-
|Lipoma||Disease||
|
|
|
|
|
|
|
|-
|Angiolipoma||Disease||
|
|
|
|
|
|
|
|-
|Liposarcoma||Disease||
|
|
|
|
|
|
|
|-
|Pseudoangiomatous stromal hyperplasia||Disease||
|
|
|
|
|
|
|
|-
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)||Disease||
|
|
|
|
|
|
|
|-
|Follicular lymphoma||Disease||
|
|
|
|
|
|
|
|-
|Diffuse large B-cell lymphoma||Disease||
|
|
|
|
|
|
|
|-
|Burkitt lymphoma||Disease||
|
|
|
|
|
|
|
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease||
|
|
|
|
|
|
|
|-
|Gynaecomastia||Disease||
|
|
|
|
|
|
|
|-
|Carcinoma in situ||Disease||
|
|
|
|
|
|
|
|-
|Invasive carcinoma||Disease||
|
|
|
|
|
|
|
|-
|Metastases to the breast||Disease||
|
|
|
|
|
|
|
|-
|BRCA1/2-associated hereditary breast and ovarian cancer syndrome||Disease||
|
|
|
|
|
|
|
|-
|Cowden syndrome||Disease||
|
|
|
|
|
|
|
|
|-
|Ataxia-telangiectasia||Disease||
|
|
|
|
Line 4,782: Line 2,776:
|
|
|-
|-
|Li-Fraumeni syndrome, TP53-associated||Disease||
|
|
|
|
|
|
|
|
|
|-
|Li-Fraumeni syndrome, CHEK2-associated||Disease||
|
|
|
|
Line 4,800: Line 2,786:
|
|
|-
|-
|CDH1-associated breast cancer||Disease||
|
|
|
|
|
|
|
|
|
|
|
|-
|PALB2-associated cancers||Disease||
|
|
|
|
Line 4,815: Line 2,795:
|
|
|
|
|
|
|-
|Peutz-Jeghers syndrome||Disease||
|
|
|
|
|
|
|
|-
|Neurofibromatosis type 1||Disease||
|
|
|
|
|
|
|
|-
|}
|}
​
​
Retrieved from "https://content.ccga.io/index.php/Volunteer_Assignments_and_Opportunities"